GlaxoSmithKline / Flickr.com
India’s Intellectual Property Appeal Board (IPAB) has revoked a patent covering GlaxoSmithKline’s (GSK) breast cancer drug Tykerb, in the latest blow to western pharmaceutical companies in India.
If you have already subscribed please login.
If you have any technical issues please email tech support.
glaxosmithkline, section 3(d), ipab, Tykerb, tyverb, lapatinib,
